CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

CRISPR–Cas, a bacterial defence system that recognizes and slashes specific sequences in viral genomes, gave scientists the power to delete or edit genes with remarkable precision. Developed in ...

Copyright 2025 The Associated Press. All Rights Reserved. Copyright 2025 The Associated Press. All Rights Reserved. Three genetically engineered wolves that may ...

The CRISPR Market had an estimated market share worth USD 3.4 billion in 2023, and it is predicted to reach a global market valuation of USD 17.8 billion by 2034, growing at a CAGR of 16.1% from 2024 ...

REDWOOD CITY, Calif., April 8, 2025 /PRNewswire/ -- Synthego and Vita Therapeutics, Inc. today announced a licensing agreement to integrate Synthego's high-fidelity hfCas12Max CRISPR system into ...

In a secret location in the United States, two white wolves are lounging in the grass in a sunny, roughly one-acre enclosure. It’s early spring and a chill wind blows through bare trees nearby.

CRISPR Therapeutics has a 12-month low of $30.96 and a 12-month high of $67.88. CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th.

To achieve its goal, the company essentially created a hybrid genome using CRISPR technology to cut away certain gray wolf gene variants and replace them with traits associated with dire wolves ...

CRISPR Therapeutics experienced an 12% price decline over the last week, coinciding with significant market disruption driven by escalating tariff tensions, which saw the S&P 500 and Nasdaq drop ...

Biosensors and Nanobiotechnology Laboratory, Integrated Science Building, Faculty of Science, Universiti Brunei Darussalam, Jalan Tungku Link, Gadong BE1410, Brunei Darussalam ...